Networking & Partnering in Japan — How Foreign Companies Find Partners and Support

For foreign life-science and healthcare companies (pharmaceuticals, medical devices, IVDs, regenerative medicine, healthcare, and care tech) entering the Japanese market, this page explains how to find the partners and public support you need. A good first step is to approach your own country’s public support window — many governments help their companies enter Japan. From there, this page covers Japan’s own advisory desks, partnering events, life-science clusters, how to find each type of partner, the local partner you may be legally required to appoint, and how Japanese business customs affect partnering. Primary-source links are given throughout.

About this page

  • Start with your own country’s support window. Many governments and public bodies help their companies enter Japan; this is usually the easiest first step. This page then covers Japan’s own public desks and the rest of the partnering landscape.
  • The page is organized by how a foreign company typically proceeds: start with home-country support, then Japan’s advisory desks, events, clusters, partners by type, and the essentials of market entry.
  • Most references and official communication in Japan are in Japanese. We recommend securing a Japan-based partner or resident (even part-time) early.
  • Direct cold outreach often goes unanswered; meeting people at events and through introductions works far better.
  • Event dates, figures, and program details change yearly — confirm on each official page.

Contents

1. Home-Country Public Support

The easiest first step is often your own country’s public support window. Many governments and public institutions help their companies enter Japan — through an embassy commercial section, a dedicated soft-landing hub, or an acceleration program — and some run life-science-specific programs. These bodies can introduce you to Japanese partners, investors, and advisors in your own language.

For a directory organized by region (North America, Europe, Asia-Pacific, and the Middle East), with the responsible public body and an official link for each, see JPRO’s dedicated page:

2. Public Support in Japan (JETRO)

Japan’s main public support for foreign companies is JETRO (Japan External Trade Organization), the national investment-promotion body.

  • JETRO Invest Japan / IBSC (Invest Japan Business Support Center) — Free consultations in English, market and regulatory information, and temporary office space (up to 50 business days), at six IBSCs nationwide (Tokyo, Yokohama, Nagoya, Osaka, Kobe, Fukuoka). https://www.jetro.go.jp/en/invest/
  • Investment opportunities in Japan’s regions — JETRO also provides a directory of regional investment destinations, with each area’s target industries and the incentives offered by local governments, so you can compare prefectures and cities. https://www.jetro.go.jp/en/invest/region/

3. Partnering Events & Trade Shows

Attending an event is often the most effective way to meet Japanese partners face to face. The main life-science events with English-language support and structured partnering are below. Dates change yearly — confirm on each official page.

  • BioJapan (Yokohama) — Asia’s premier bio-industry partnering event, with an English-language one-to-one meeting system. Co-located with Regenerative Medicine JAPAN and healthTECH JAPAN. Held in October (2026: Oct 7–9, Pacifico Yokohama). https://jcd-expo.jp/en/
  • CPHI Japan (Tokyo) — Pharmaceutical ingredients, development, and CDMO/CRO. Held in April (2026: Apr 21–23, Tokyo Big Sight). https://www.cphi.com/japan/en/home.html
  • Medtec Japan (Tokyo) — Medical device design and manufacturing, held alongside CPHI Japan (2026: Apr 21–23, Tokyo Big Sight). https://www.medtecjapan.com
  • INTERPHEX Week Tokyo — Pharmaceutical manufacturing and regenerative-medicine production. Held in May (2026: May 20–22, Makuhari Messe). https://www.interphex.jp/tokyo/en-gb.html
  • Medical Japan — Medical and elderly-care industry show, held in Osaka (March) and Tokyo (October). https://www.medical-jpn.jp/tokyo/en-gb.html

4. Life-Science Clusters & Hubs

Japan’s life-science clusters and hubs are good entry points for meeting companies, renting lab or office space, and joining local events. All of the following have English-language pages and international-collaboration activity.

  • LINK-J (Nihonbashi, Tokyo) — A large life-science networking community running many English-language and international events. https://www.link-j.org/en/
  • Shonan Health Innovation Park (Shonan iPark) — Japan’s first pharma-originated science park, with international matchmaking activity. https://www.shonan-ipark.com/en/
  • Kobe Biomedical Innovation Cluster (KBIC / FBRI) — One of Japan’s largest biomedical clusters, with overseas-cluster partnerships. https://www.fbri-kobe.org/kbic/english/
  • Kawasaki King Skyfront — An international open-innovation hub near Haneda Airport; tenants are searchable by sector. https://www.king-skyfront.jp/en/
  • Greater Tokyo Biocommunity (GTB) — A government-certified global biocommunity spanning eight areas of the Greater Tokyo region. https://gtb.jba.or.jp/en/
  • Biocommunity Kansai (BiocK) — A government-certified global biocommunity for the Kansai region. https://biock.jp/en/

5. Finding Partners by Type

Different partner types are found through different directories. Below are the main English-language sources by category. Where no public English directory exists, that is noted.

6. Market Entry Essentials: The Partner You May Legally Need

To sell pharmaceuticals or medical devices in Japan, a foreign company usually needs a Japan-based partner that holds the regulatory license. This is a defining feature of the Japanese system.

  • MAH (Marketing Authorization Holder) — A licensed entity in Japan that holds the approval and takes responsibility for quality (QMS) and post-market safety (GVP). The MAH owns the approval.
  • DMAH (Designated Marketing Authorization Holder) — Under the foreign special-approval system, a foreign manufacturer can hold the approval while a DMAH acts as its in-country agent. This route is available only to overseas companies.
  • No public list of MAHs/DMAHs exists. PMDA does not provide one, so foreign companies find these partners through industry associations (JPMA, JFMDA, JCROA), service providers, or events.

For details, see JPRO’s English pages on DMAH (Designated Marketing Authorization Holder) and PMDA Consultation Guide for Foreign Companies.

7. A Note on Japanese Business Customs

Some accounts — often from consultants who have an interest in the claim, since “you need connections” is also a reason to hire them — stress that partnering in Japan depends on personal relationships. In our experience, that is misleading. Japanese companies evaluate proposals rationally: if your product or technology is genuinely good and solves a real problem, it will be judged on its merits.

It also helps to understand how decisions are actually made. In Japan, unless you are dealing with a founder-owner, no single individual drives a corporate decision; choices are made collectively (group decision-making). A personal connection or one person’s recommendation is therefore not enough to move a large company — just as it would not be in a Western corporation. What moves the decision is a proposal strong enough to win internal consensus.

A few practical points still hold:

  • Share materials in advance. Japanese participants often speak up less in meetings, partly because of the language barrier. Sending documents beforehand gives them time to understand your proposal and makes the discussion more productive.
  • A “yes” is not always a yes. Japanese counterparts are often reluctant to say something negative directly, especially to a foreign company. A polite, non-committal response can in fact mean “no.” Watch for what is not said, and do not read a vague but pleasant reply as a green light.
  • Decisions take time. Because consensus is built internally before a company commits (nemawashi), early meetings may not produce a quick answer. This is process, not disinterest.
  • Language matters. Most official communication is in Japanese — and much of the real message lives between the lines.

Ideally, work with a Japan-based liaison who can read those nuances — not just translate the language, but tell you what a response actually means. This is also one more reason why drawing on your embassy or a home-country public support organization makes sense: they can act as a trusted, publicly backed bridge into the Japanese market. Above all, lead with the quality of your product or technology, and give the other side what they need to build internal agreement. That is what Japanese companies respond to.

8. References & Related JPRO Pages

Primary sources referenced on this page — the official pages of the organizations, events, and programs above (see the links in each section).

Related JPRO pages:

Table of Contents 
About ​JPRO
​Services
Contact Us
​​コンテンツ一覧
​オフィス概要
本サイトは、主にヘルスケア領域での起業・社会実装を目指す方のための情報サイトです。公的機関でアドバイザーを務める著者が、起業家が十分な知識を持ち、外部に過度に依存せず主体的に事業化を進められるよう、プロボノ活動の一環として運営しています。薬事等の法規制から資金調達、事業開発、知財など必要な情報をワンストップで収集できます。掲載情報は信頼性の高い公的機関の一次資料に基づいています。
This portal supports international healthcare enterprises and innovators expanding into the Japanese market. Operated as a pro bono initiative by an advisor to Japanese public institutions, the site is designed to equip you with the knowledge needed to advance your business proactively, without over-reliance on external consultants. From regulatory affairs to business setups, all content is sourced only from highly reliable public institutions. ©2026 JPRO